Reemphasis on lymphoblast L2 morphology as a poor prognostic factor in childhood acute lymphoblastic leukemia

Medical and Pediatric Oncology

Volumn 33, Issue 4, 1999, Pages 388-394

  Kanerva, Jukka ^a   Saarinen Pihkala, Ulla M ^a   Riikonen, Pekka ^b   Mäkipernaa, Anne ^c   Möttönen, Merja ^d   Salmi, Toivo T ^e  

^a UNIVERSITY OF HELSINKI   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d OULU UNIVERSITY HOSPITAL   (Finland)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Childhood ALL; Leukemia; Lymphoblast; Lymphoblast morphology; Morphology; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL STRUCTURE; CHILD; CHILDHOOD CANCER; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOBLAST; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; MALE; PROGNOSIS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0032836955     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199910)33:4<388::AID-MPO8>3.0.CO;2-N     Document Type: Article

References (21)

1. Margolin JF, Poplack DG. Acute lymphoblastic leukemia. In Pizzo P, Poplack D, editors. Principles and practice in pediatric oncology, 3rd ed. Philadelphia: J.B. Lippincott Company; 1997. p 409-462.
2. Hammond D, Sather H, Nesbit M, et al. Analysis of prognostic factors in acute lymphoblastic leukemia. Med Pediatr Oncol 1986; 14:124-134.
3. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24.
4. Miller DR, Leikin S, Albo V, et al. Use of prognostic factors in improving the design and efficiency of clinical trials in childhood leukemia: Children's Cancer Study Group report. Cancer Treat Rep 1980;64:381-392.
5. Miller DR, Leikin S, Albo V, et al. Prognostic importance of morphology (FAB classification) in childhood acute lymphoblastic leukaemia (ALL). Br J Haematol 1981;48:199-206.
6. Miller DR, Krailo M, Bleyer WA, et al. Prognostic implications of blast cell morphology in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. Cancer Treat Rep 1985;69:1211-1221.
7. Kalwinsky DK, Roberson P, Dahl G, et al. Clinical relevance of lymphoblast biological features in children with acute lymphoblastic leukemia. J Clin Oncol 1985;3:477-484.
8. Lilleyman JS, Hann IM, Stevens RF, et al. Cytomorphology of childhood lymphoblastic leukaemia: a prospective study of 2000 patients. United Kingdom Medical Research Council's Working Party on Childhood Leukaemia. Br J Haematol 1992;81:52-57.
9. van Eys J, Pullen J, Head D, et al. The French-American-British (FAB) classification of leukemia. The Pediatric Oncology Group experience with lymphocytic leukemia. Cancer 1986;57:1046-1051.
10. Steinherz PG, Gaynon PS, Breneman JC, et al. Cytoreduction and prognosis in acute lymphoblastic leukemia - the importance of early marrow response: report from the Childrens Cancer Group. J Clin Oncol 1006;14:389-398.
11. Lilleyman JS, Gibson BE, Stevens RF, et al. Clearance of marrow infiltration after 1 week of therapy for childhood lymphoblastic leukaemia: clinical importance and the effect of daunorubicin. The Medical Research Council's Working Party on Childhood Leukaemia. Br J Haematol 1997;97:603-606.
12. Schultz KR, Massing B, Spinelli JJ, et al. Importance of the day 7 bone marrow biopsy as a prognostic measure of the outcome in children with acute lymphoblastic leukemia. Med Pediatr Oncol 1997;29:16-22.
13. Gustafsson G, Kreuger A, Clausen N, et al. Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non-high-risk patients: the Nordic experience of 2648 patients diagnosed between 1981 and 1996. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Acta Paediatr 1998;87:1151-1161.
14. Kanerva J, Tiirikainen M, Makipernaa A, et al. Multiple drug resistance mediated by P-glycoprotein is not a major factor in a slow response to therapy in childhood ALL. Pediatr Hematol Oncol 1998;15:11-21.
15. 2). N Engl J Med 1983;308:559-565.
16. Stewart EL, Secker-Walker LM. Detection of the chromosomally abnormal clone in acute lymphoblastic leukemia. Cancer Genet Cytogenet 1986;23:25-35.
17. Loffler H, Kayser W, Schmitz N, et al. Morphological and cytochemical classification of adult acute leukemias in two multicenter studies in the Federal Republic of Germany. Hamatol Bluttrans 1987;30:21-27.
18. Hoelzer D: Acute Lymphoblastic leukemia in adults. In Hoffman R, Benz EJ Jr, Shattil SJ, et al., editors. Hematology: basic principles and practice, Vol 1, 2nd ed. New York: Churchill Livingstone, 1995. p 1084-1098.
19. Howard MR, Thomas L, Reid MM. Variable detection of myeloid antigens in childhood acute lymphoblastic leukaemia. J Clin Pathol 1994;47:1006-1009.
20. McLean TW, Ringold S, Neuberg D, et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996;88:4252-4258.
21. Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995;9:1985-1989.